| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/JVH.12237 |
| P698 | PubMed publication ID | 24612466 |
| P50 | author | Fabien Zoulim | Q33116701 |
| P2093 | author name string | M Amiri | |
| M Maynard | |||
| F Bailly | |||
| F Gonçalves | |||
| G Funingana | |||
| K Hartig-Lavie | |||
| P Pradat | |||
| V Virlogeux | |||
| P2860 | cites work | Boceprevir for previously treated chronic HCV genotype 1 infection | Q24620576 |
| What is meant by intention to treat analysis? Survey of published randomised controlled trials | Q24647858 | ||
| Antiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated condition | Q27490340 | ||
| Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 | ||
| Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Q27860949 | ||
| Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance | Q28255243 | ||
| The model for end-stage liver disease (MELD) | Q28290440 | ||
| Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups | Q29614459 | ||
| A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group | Q29614889 | ||
| IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy | Q29614896 | ||
| Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C | Q29619541 | ||
| Telaprevir for previously untreated chronic hepatitis C virus infection | Q29619800 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| The global burden of hepatitis C | Q29620138 | ||
| Boceprevir for untreated chronic HCV genotype 1 infection | Q29620617 | ||
| Hepatitis C virus infection in Western Europe | Q33809464 | ||
| Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. | Q34390093 | ||
| Response-guided telaprevir combination treatment for hepatitis C virus infection | Q34632295 | ||
| Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. | Q36683930 | ||
| A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. | Q37992195 | ||
| New antiviral therapies in the management of HCV infection | Q38012912 | ||
| Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care | Q38014646 | ||
| Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents | Q39601072 | ||
| Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir | Q42286983 | ||
| Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms | Q42644926 | ||
| Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. | Q42987322 | ||
| Low glomerular filtration rate is a risk factor for ribavirin-associated anaemia in old patients with chronic hepatitis C. | Q43974244 | ||
| Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters | Q47248395 | ||
| P433 | issue | 9 | |
| P921 | main subject | virology | Q7215 |
| end-stage liver disease | Q54974362 | ||
| chronic hepatitis C | Q55779873 | ||
| P304 | page(s) | e98-e107 | |
| P577 | publication date | 2014-02-25 | |
| P1433 | published in | Journal of Viral Hepatitis | Q15749962 |
| P1476 | title | Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score | |
| P478 | volume | 21 |
| Q28070279 | Anti-hepatitis C virus drugs and kidney |
| Q38515906 | Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace |
| Q34966853 | Hepatitis C and kidney disease: An overview and approach to management |
| Q40403305 | Liver Apparent Diffusion Coefficient Changes during Telaprevir-Based Therapy for Chronic Hepatitis C. |
| Q38249065 | Optimizing triple therapy and IFN/RBV-free regimens for hepatitis C virus infection |
| Q41655360 | Patients treated with first-generation HCV protease inhibitors exhibit high ribavirin concentrations. |
| Q64943628 | Possible Simeprevir/Sofosbuvir-Induced Hepatic Decompensation With Acute Kidney Failure. |
| Q34330704 | Prediction of Sustained Virological Response to Telaprevir-Based Triple Therapy Using Viral Response within 2 Weeks. |
| Q35553310 | Short and long-term effects of telaprevir on kidney function in patients with hepatitis C virus infection: a retrospective cohort study |
| Q38435340 | Telaprevir-induced renal impairment: three clinical cases and a review of the literature |
| Q40215846 | The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir-based regimens |
| Q39249225 | Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients |
| Q41934901 | When and how can nephrologists treat hepatitis C virus infection in dialysis patients? |
Search more.